Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019084 | 0.81 | MAP4K4 (0.64) | DHFRPIK3CGDCPSMAP4K4 | |
| SCHEMBL4353706 | 0.78 | MAP4K4 (0.61) | DHFRDCPSMAP4K4 | |
| SCHEMBL4351919 | 0.78 | DHFR (0.58) | DHFRMAP4K4 | |
| SCHEMBL4755412 | 0.77 | DCPS (0.53) | DHFRDCPS | |
| SCHEMBL13019082 | 0.75 | DYRK1A (0.46) | PIK3CGAPPMAP4K4 | |
| SCHEMBL13019080 | 0.75 | APP (0.48) | PIK3CGAPP | |
| SCHEMBL13019078 | 0.75 | SRC (0.67) | PIK3CGAPP | |
| SCHEMBL4362768 | 0.73 | DHFR (0.69) | DHFR | |
| Quinazoline-2,4,6-Triamine SCHEMBL30050079 | 0.72 | DCPS (0.57) | DHFRDCPS | |
| Quinazoline-2,4,6-Triamine SCHEMBL335027 | 0.72 | DCPS (0.57) | DHFRDCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | DHFR 1951/4885PIK3CG 2378/4885APP 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.